Stockreport

Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF positive Phase 1b/2 results for REC-4881, which is its investigational allosteric MEK1/2 inhibitor designed to treat Familial Adenomatous Polyposis/FAP. FAP is a rare, [Read more]